Several other research firms have also recently commented on SN. Numis Securities raised their price target on shares of Smith & Nephew from GBX 1,350 ($17.64) to GBX 1,480 ($19.34) and gave the stock an add rating in a report on Thursday, July 26th. UBS Group cut shares of Smith & Nephew to a neutral rating and decreased their price target for the stock from GBX 1,470 ($19.21) to GBX 1,340 ($17.51) in a report on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of GBX 1,391.45 ($18.18).
SN stock opened at GBX 1,333.50 ($17.42) on Friday. Smith & Nephew has a 52 week low of GBX 1,173 ($15.33) and a 52 week high of GBX 1,442 ($18.84).
In other Smith & Nephew news, insider Erik Engstrom bought 249 shares of Smith & Nephew stock in a transaction on Thursday, August 23rd. The stock was purchased at an average cost of GBX 1,380 ($18.03) per share, for a total transaction of £3,436.20 ($4,490.00). Also, insider Graham Baker bought 19 shares of Smith & Nephew stock in a transaction on Thursday, August 2nd. The stock was acquired at an average price of GBX 1,331 ($17.39) per share, with a total value of £252.89 ($330.45).
About Smith & Nephew
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Featured Story: Do You Need a Fiduciary?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.